Tryp Therapeutics strengthens intellectual property portfolio

KELOWNA, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) — tryp therapeuticsinc TRYP TRYPF (“Attempt” or the “company“), a clinical-stage biotechnology company focused on the development of psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of two new provisional patent applications. One patent application, #63/405,786, relates to the use of Psilocybin for the treatment of patients with fibromyalgia and the other application, Serial No. 63/375,305, expand the IP related to the Company’s development of TRP-8803.

Jim Gilligan, Chief Executive Officer of Tryp Therapeutics, commented, “Tryp is taking an innovative approach to expand treatment options for patients with nociplastic pain and eating disorders who have been unsuccessful with currently approved drugs. We are systematically expanding our patent portfolio and remain committed to developing a combined psychedelic and psychotherapeutic treatment for patients suffering from the debilitating effects of conditions such as fibromyalgia and binge eating disorder.”

The Company is preparing for a Phase 2a clinical trial in collaboration with the University of Michigan to evaluate the safety and preliminary efficacy of psilocybin-assisted therapy in patients with fibromyalgia. The clinical studies are expected to support Tryp’s positive preclinical results in an animal model of nociplastic pain. Once granted, the new patent will grant Tryp intellectual property protection for fibromyalgia using its psilocybin-based candidates.

About Fibromyalgia (FM)

• Fibromyalgia is characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood problems
• Existing treatments have limited effectiveness and significant side effects
• Less than 10% of patients are adhering to approved treatments after one year
• ~30% of patients take opioids despite lack of evidence of efficacy and risk of addiction and/or overdose

Tryp uses TRP-8802 to…